Abstract
Noncoding RNAs play a part in many chronic diseases and interact with each other to regulate gene expression. MicroRNA-9-5p (miR9) has been thought to be a potential inhibitor of diabetic cardiomyopathy. Here we examined the role of miR9 in regulating cardiac fibrosis in the context of diabetic cardiomyopathy. We further expanded our studies through investigation of a regulatory circularRNA, circRNA_012164, on the action of miR9. We showed at both the in vivo and in vitro level that glucose induced downregulation of miR9 and upregulation of circRNA_012164 resulted in the subsequent upregulation of downstream fibrotic genes. Further, knockdown of circRNA_012164 shows protective effects in cardiac endothelial cells and reverses increased transcription of genes associated with fibrosis and fibroblast proliferation through a regulatory axis with miR9. This study presents a novel regulatory axis involving noncoding RNA that is evidently important in the development of cardiac fibrosis in diabetic cardiomyopathy.
Funder
Canadian Institutes of Health Research
Publisher
Public Library of Science (PLoS)
Reference65 articles.
1. Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025;X Lin;Sci Rep,2020
2. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045;NH Cho;Diabetes Research and Clinical Practice,2018
3. Metabolic Control of Type 2 Diabetes by Targeting the GLUT4 Glucose Transporter: Intervention Approaches;F Alam;Curr Pharm Des,2016
4. Physiology, Glucose Transporter Type 4. In: StatPearls;StatPearls Publishing;Treasure Island (FL),2023
5. Endothelial-to-mesenchymal transition: An underappreciated mediator of diabetic complications;E Wang;Frontiers in Endocrinology,2023